FDA proposes ending use of oral phenylephrine as OTC nasal decongestant

Phenylephrine as an oral decongestant

• Broad consensus that oral phenylephrine (PE) “doesn’t work” for congestion; many call it a scam/placebo that’s been obvious in real‑world use for years.
• Some report mild or situational benefit, or relief only when combined with other actives (e.g., aspirin, acetaminophen, ibuprofen), raising the possibility they’re feeling the other ingredients.
• Multiple comments note that PE is effective in other routes:
  • Intranasal sprays and inhalers are widely described as actually working.
  • IV phenylephrine is noted as a powerful vasoconstrictor in anesthesia/critical care.
• Explanation repeated: poor oral bioavailability; metabolized before it reaches the bloodstream.
• Many criticize pharma companies for knowingly selling ineffective PE formulations for decades.

Pseudoephedrine: effectiveness and access restrictions

• Strong agreement that pseudoephedrine is highly effective for congestion and ear/sinus pressure (including flying and preventing ear damage).
• In the US and some other countries it’s “behind the counter” with ID checks, quantity limits, and registries due to meth production.
• Some find limits generous and easy (e.g., 30‑day supply), others hit caps due to chronic allergies or family use and find it a serious hassle.
• Workarounds discussed: prescriptions (which may bypass quantity limits in some states), bringing a “buddy,” or stockpiling.
• Debate on policy impact:
  • One side: restrictions reduced small “garage” labs and dangerous home meth production.
  • Other side: meth supply simply shifted to industrial P2P routes; restrictions mainly inconvenience legitimate users and didn’t curb use.

Trust in FDA and regulation

• Many see the long delay in acting against oral PE as a major hit to FDA credibility: “obviously ineffective” yet allowed for decades.
• Others emphasize that institutions make mistakes but can self‑correct; question whether this is representative or an outlier.
• Discussion of regulatory roles: distinguishing manufacturing quality, safety, and efficacy; contrast with largely unregulated supplements and homeopathy sold alongside real drugs.

Alternatives and practical advice

• Commonly recommended:
  • Nasal saline rinses/neti pots (with repeated warnings to use sterile/distilled water).
  • Intranasal corticosteroid sprays (noted as safe long‑term when used nasally).
  • Oxymetazoline / xylometazoline sprays (very effective but risk rebound congestion and dependence with overuse).
  • Guaifenesin + dextromethorphan for chest symptoms; some argue guaifenesin is ineffective, others report benefit.
• Several users describe structural or chronic issues (deviated septum, turbinate problems) and report surgery or procedures (e.g., chemical nasal cautery) as life‑changing.

Broader policy and societal themes

• Thread repeatedly links pseudoephedrine restrictions to the war on drugs, neoliberal or punitive policy, and “nanny state” overreach.
• Some argue virtually all non‑addictive or non–“commons” drugs should be OTC; others stress real cardiovascular risks of decongestants, especially in people with hypertension.
• International notes:
  • Some countries have made pseudoephedrine prescription‑only or very restricted; others allow easier OTC access.
  • Availability patterns (and follow‑on impacts on meth supply) differ across Europe, Australasia, and parts of Asia.